According to Ipsen's statement, Henri Beaufour was an active member of the board and a representative of the founding family. Alongside his sister Anne, he contributed to the support of the company's strategic direction and the maintenance of family values. Henri Beaufour, also an artist, was recognized for his generosity and humanity. Beech Tree and Highrock, the majority shareholders, affirm their intention to continue working together for the group's interest.
Tributes from Ipsen's Leadership
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Marc de Garidel, Chairman of Ipsen, expressed his sorrow at the loss of Henri Beaufour and praised his role in the company's development. David Loew, CEO, also shared his condolences and declared the management's commitment to continue developing Ipsen in tribute to Henri Beaufour.
About Ipsen
Ipsen is a global biopharmaceutical group, specializing in the development of innovative drugs in the fields of oncology, rare diseases, and neuroscience. Present in over 40 countries, Ipsen has research hubs in France, the United States, and the United Kingdom, and its products are distributed in over 100 countries.
"En 2025, Ipsen a enregistré une croissance solide de son chiffre d'affaires et de son résultat opérationnel."
Ipsen a publié ses résultats 2025 et T4 2025: chiffre d'affaires de 3 675,9 millions d'euros, croissance YoY de 8,1%; Résultat opérationnel des activités de 1 294,1 millions d'euros, marge de 35,2%; Résultat net consolidé IFRS de 444,5 millions d'euros; Bénéfice dilué par action IFRS de 5,32 euros; Cash-flow libre de 1 000,6 millions d'euros; Dividende par action de 1,40 euro.
Outlook / guidance
Expected revenue: Une croissance des ventes totales supérieure à 13,0 % à taux de change constant en 2026
Management commentary: Ipsen prévoit en 2026 une croissance des ventes totales supérieure à 13,0% à taux de change constant et une marge opérationnelle des activités supérieure à 35,0%.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
